These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 14726144)

  • 1. Alternative sugars as potential carriers for dry powder inhalations.
    Steckel H; Bolzen N
    Int J Pharm; 2004 Feb; 270(1-2):297-306. PubMed ID: 14726144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of carrier on the performance of dry powder inhalers.
    Saint-Lorant G; Leterme P; Gayot A; Flament MP
    Int J Pharm; 2007 Apr; 334(1-2):85-91. PubMed ID: 17113733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation into alternative sugars as potential carriers for dry powder formulation of budesonide.
    Momin MN; Hedayati A; Nokhodchi A
    Bioimpacts; 2011; 1(2):105-11. PubMed ID: 23678414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers.
    Schiavone H; Palakodaty S; Clark A; York P; Tzannis ST
    Int J Pharm; 2004 Aug; 281(1-2):55-66. PubMed ID: 15288343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dry powder inhaler performance of spray dried mannitol with tailored surface morphologies as carrier and salbutamol sulphate.
    Mönckedieck M; Kamplade J; Fakner P; Urbanetz NA; Walzel P; Steckel H; Scherließ R
    Int J Pharm; 2017 May; 524(1-2):351-363. PubMed ID: 28347847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budesonide dry powder for inhalation: effects of leucine and mannitol on the efficiency of delivery.
    Rattanupatam T; Srichana T
    Drug Deliv; 2014 Sep; 21(6):397-405. PubMed ID: 24401124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The enhanced aerosol performance of salbutamol from dry powders containing engineered mannitol as excipient.
    Kaialy W; Martin GP; Ticehurst MD; Momin MN; Nokhodchi A
    Int J Pharm; 2010 Jun; 392(1-2):178-88. PubMed ID: 20363301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the cohesion-adhesion balance approach to colloidal probe atomic force microscopy and the measurement of Hansen partial solubility parameters by inverse gas chromatography for the prediction of dry powder inhalation performance.
    Jones MD; Buckton G
    Int J Pharm; 2016 Jul; 509(1-2):419-430. PubMed ID: 27265314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lactose modifications enhance its drug performance in the novel multiple dose Taifun DPI.
    Harjunen P; Lehto VP; Martimo K; Suihko E; Lankinen T; Paronen P; Järvinen K
    Eur J Pharm Sci; 2002 Sep; 16(4-5):313-21. PubMed ID: 12208462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of realistic inspiratory flow profiles on fine particle fractions of dry powder aerosol formulations.
    Martin GP; Marriott C; Zeng XM
    Pharm Res; 2007 Feb; 24(2):361-9. PubMed ID: 17177114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Particle engineered mannitol for carrier-based inhalation - A serious alternative?
    Hertel N; Birk G; Scherließ R
    Int J Pharm; 2020 Mar; 577():118901. PubMed ID: 31846726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
    Marriott C; MacRitchie HB; Zeng XM; Martin GP
    Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adhesion and redistribution of salmeterol xinafoate particles in sugar-based mixtures for inhalation.
    Adi H; Larson I; Stewart PJ
    Int J Pharm; 2007 Jun; 337(1-2):229-38. PubMed ID: 17303354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations.
    Price R; Young PM; Edge S; Staniforth JN
    Int J Pharm; 2002 Oct; 246(1-2):47-59. PubMed ID: 12270608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineered mannitol as an alternative carrier to enhance deep lung penetration of salbutamol sulphate from dry powder inhaler.
    Kaialy W; Momin MN; Ticehurst MD; Murphy J; Nokhodchi A
    Colloids Surf B Biointerfaces; 2010 Sep; 79(2):345-56. PubMed ID: 20537870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lactose as a carrier in dry powder formulations: the influence of surface characteristics on drug delivery.
    Zeng XM; Martin GP; Marriott C; Pritchard J
    J Pharm Sci; 2001 Sep; 90(9):1424-34. PubMed ID: 11745794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dry powder aerosols generated by standardized entrainment tubes from alternative sugar blends: 3. Trehalose dihydrate and D-mannitol carriers.
    Mansour HM; Xu Z; Hickey AJ
    J Pharm Sci; 2010 Aug; 99(8):3430-41. PubMed ID: 20229601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining the critical material attributes of lactose monohydrate in carrier based dry powder inhaler formulations using artificial neural networks.
    Kinnunen H; Hebbink G; Peters H; Shur J; Price R
    AAPS PharmSciTech; 2014 Aug; 15(4):1009-20. PubMed ID: 24831088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.